# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-30 (automated, unattended)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot comparison, and web breaking-news check. No existing files were modified.

Confidence tags follow the Research Doctrine: **[Certain]** = read directly from files / independently verifiable, **[Likely]** = strong inference, **[Guessing]** = gap-filling.

---

## Headline (read this first)

**The two baseline data pipelines are still frozen at 2026-07-17 — now 13 days stale, and unchanged since yesterday's run.** `clinical_trials_latest.json` and `pubmed_recent_latest.json` have not been regenerated. No new trial snapshots or PubMed snapshots have appeared. There is **no genuinely new trial or publication activity to report** this cycle — everything below is either the frozen 07-17 state or context carried forward.

The gap-analysis and agent-state pipelines are still alive (agent_state backed up 07-29, gap report regenerated 07-29), but they are re-processing the same 07-17 source data. **Priority action is unchanged from yesterday: manually re-run `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py`.** Two consecutive stale cycles suggests these jobs are failing silently or were disabled, not just skipped once.

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `hub_monitor_report.md` | 2026-07-17 | 13 d | **Stale** |
| `clinical_trials_latest.json` | 2026-07-17 | 13 d | **Stale** |
| `pubmed_recent_latest.json` | 2026-07-17 | 13 d | **Stale** |
| `literature_gap_data.json` | 2026-07-18 | 12 d | Aging |
| `literature_gap_report.md` | 2026-07-29 | 1 d | Fresh (but built on 07-17 source range) |
| `agent_state.json` | 2026-07-29 | 1 d | Fresh |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | 13 d | **Stale** |

- Latest trial snapshot: `clinical_trials_snapshot_2026-07-17.json` — **no snapshots for 13 days.** [Certain]
- Latest PubMed snapshot: `pubmed_recent_snapshot_2026-07-17.json` — same gap. [Certain]
- The gap report (`literature_gap_report.md`) re-ran 07-29 but its own header states the data range ends **2026/07/17** — confirming the PubMed feed underneath it has not advanced. [Certain]
- The 07-17 hub monitor already flagged **827 result files older than 14 days**; that backlog has only grown. [Certain]

**Interpretation [Likely]:** `hub_monitor.py`, the gap runner, and the agent-state backup still fire on schedule. `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py` stopped producing output after 07-17 and have not recovered.

---

## Clinical Trial Changes

Source: `clinical_trials_latest.json` (2026-07-17). **858 trials** across five categories — T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies 147, Devices 236, Recently Completed w/ Results 321. [Certain]

**No new snapshot diff exists since 07-17.** For context, the last *real* week of data (07-10 → 07-17) showed +8 new trials, −2 removed, 6 status changes. [Certain] Notable status changes in that window: three AstraZeneca elecoglipr(`NCT07662044/07662213/07662109/07662135`) Phase III trials moved NOT_YET_RECRUITING → RECRUITING, and a Novo Nordisk Phase 2 (`NCT07668388`) opened for recruitment.

### Phase 3 RECRUITING — key-organization trials to watch [Certain]

| NCT | Sponsor | Therapy / focus |
|-----|---------|-----------------|
| NCT06832410 | Vertex | VX-880 / zimislecel (islet cell therapy) — Phase 3 |
| NCT04786262 | Vertex | VX-880 safety/efficacy |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) in T1D |
| NCT07564414 | Novo Nordisk | CagriSema Phase 3 |
| NCT07222332 | Eli Lilly | Baricitinib — preserve beta-cell function (children) |
| NCT07222137 | Eli Lilly | Baricitinib — delay Stage 3 T1D |
| NCT07088068 | Sanofi | Teplizumab head-to-head Phase 3 |

52 Phase 3 recruiting trials total. The two Lilly baricitinib trials, the Sanofi teplizumab trial, and both Vertex zimislecel trials all track key therapies on our watchlist.

### Recently posted results (frozen list, 07-17) [Certain]

- **NCT06010004 — Eli Lilly, orforglipron long-term safety (T2D)** — results posted 2026-06-30. Watchlist hit.
- NCT05086445 — Lilly, LY3502970 (orforglipron) in Japanese T2D — posted 2026-07-16.
- NCT05574699 — closed-loop + social-risk clinical decision support — posted 2026-07-15.
- NCT05254002 — Bayer/finerenone combination — posted 2026-07-13.

These are already ~2 weeks old; treat as reviewed unless the tracker still lists them open.

---

## PubMed Highlights

Source: `pubmed_recent_latest.json` (2026-07-17, 30-day lookback, 158 unique papers). Frozen — same corpus as last cycle. [Certain]

**Cross-domain papers (highest value, 12 total).** Top hits:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — spans **AI/ML + Closed Loop AP + Health Equity** (3 domains). Directly relevant to our Tier-1 equity focus.
- **[42419792]** *Comparative effects of drugs for overweight/obesity (systematic review)* — spans **orforglipron + retatrutide + CagriSema** (3 key therapies at once).
- [42437645] GLP-1 receptor variant pharmacophoric shifts — **GLP-1 Pharmacogenomics + orforglipron**.
- [42411999] T1D driven by residual recipient T cells after HSCT — **Stem Cell Cure + Immunotherapy**.
- [42436543] Healthcare inequalities in T2D — **T2D Remission + Health Equity**.

**Key-therapy mentions (30-day counts):** dapagliflozin 52, orforglipron 10, CagriSema 6, retatrutide 4, teplizumab 4, icodec 3, baricitinib 2, **zimislecel 0**. [Certain] The zimislecel literature gap persists despite an active Phase 3 program — worth a targeted manual search.

**Domain volume (30-day):** AI/ML (260) and Microbiome (186) lead; GLP-1 Pharmacogenomics (1) and Epigenetics (5) are thinnest. No trend read is meaningful until the feed refreshes. [Certain]

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (regenerated 07-29, data range through 07-17). Validation level **BRONZE** — single analytical source, requires expert confirmation. [Certain]

Top under-researched intersections (Gap Score 100 = zero joint publications):

1. **Treg / CAR-T × Neuropathy** — 100.0, 0 joint pubs
2. **Beta Cell Regen × Health Equity** — 100.0, 0
3. **Treg / CAR-T × Health Equity** — 100.0, 0
4. **Glucokinase × Health Equity** — 100.0, 0
5. **Gene Therapy × LADA** — 100.0, 0

(Also flagged: Drug Repurposing × Health Equity 100.0; Insulin Resistance × Islet Transplant 91.9.)

**Tier-1 alignment [Likely]:** Four of the top five involve **Health Equity** or **Beta Cell Regen / cell-therapy access** — both named Tier-1 contribution areas in the doctrine. The Beta Cell Regen × Health Equity and Treg/CAR-T × Health Equity gaps are the strongest fit for a computational literature-synthesis contribution. Before acting, verify each is a real gap (not a keyword artifact) with a combined-term PubMed search and a Cochrane/PROSPERO check, per doctrine.

---

## Breaking News (web check, last 7 days)

**No genuinely new (last-7-day) major event confirmed.** [Certain]

Standing context, not new this week: the FDA granted **accelerated approval of Tzield (teplizumab, Sanofi) for Stage 3 T1D in children aged 8–17** on **2026-06-12** (~7 weeks ago), based on the Phase III **PROTECT** trial (n=328; significant C-peptide preservation at 78 weeks). This is the first disease-modifying therapy for newly diagnosed Stage 3 pediatric T1D and is directly relevant to the teplizumab watchlist and Sanofi trial NCT07088068. If the tracker does not already record this approval, add it.

Vertex zimislecel (VX-880): regulatory submissions to FDA/EMA/MHRA are expected during 2026; no confirmed new July-2026 filing or decision found this cycle. [Likely]

---

## Recommended Actions

1. **Re-run the two stalled baseline scripts immediately** — second consecutive stale cycle:
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   Then check their logs; silent failure across 13 days points to an API-key, network, or scheduler issue rather than a one-off skip.
2. **Diagnose the scheduler** — confirm why gap/agent-state jobs run but the two baseline jobs do not. If they share a cron/task runner, one disabled entry or a changed hub-root path (note the 07-17 report references `/sessions/intelligent-bold-bardeen/...`) may be the cause.
3. **Update the tracker** with the Tzield Stage 3 pediatric approval (2026-06-12) if not already logged — it graduates teplizumab from watchlist to approved for this indication.
4. **Targeted manual PubMed pull for `zimislecel`** — 0 hits in the frozen feed despite an active Phase 3; likely a query/terminology gap worth patching in `baseline_pubmed_alerts.py`.
5. **Do not treat gap findings as actionable yet** — they are BRONZE. If pursuing the Health-Equity × cell-therapy intersections, run the doctrine's verification (combined-term search + Cochrane/PROSPERO) to lift them toward SILVER.
6. **Refresh the gap analysis after the PubMed feed recovers** — the current 07-29 gap report is built on 07-17 data, so re-run `project1_literature_gap_analysis.py` once baselines are current.

---

*Generated by the Diabetes Research Hub automated monitor — 2026-07-30. Review-only run; no source files modified.*
